Tetsuya Mitsudomi

Professor, Thoracic Surgery, Kindai University, Osaka, Japan, Interested in Translational research of lung cancer. Play the cello a little bit.

[Jose Fernando Moura, PhD @FernandoOnco]

WCLC 2026: os 40 estudos de câncer de pulmão que estou de olho ��� @GBOT_Alerta @IASLC #wclc26

[Dr Tatsu@越境医 @TatsuDr33]

世界的な権威雑誌「Lancet」が日本の医療制度を単独特集するのは、実に15年ぶり。

東北大学主導、25人の研究者による政策提言論文が7月16日に発表された。結論は厳しくて「小さな修正では持たない」

https://t.co/BO18SrxCzW

[くまらぼ @hiro44_pino]

Claude Codeだけ触って
Claude使いこなしてますの人
正直浅すぎるでしょっw w

Claudeの本体って
コード生成だけじゃない

むしろ仕事で効くのは、
・Coworkで作���部屋を作る
・Projectsで前提を覚えさせる　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　
・Artifactsで小さいツールを作る
・Designでたたき台を出す
・Connectorsで外部情報を拾う
・Skillsでいつもの作業を呼び出す
この辺かな

毎回チャット欄に長文プロンプト
貼ってる時点で、だいぶもったいない

これから強いのはAIに質問する人じゃなくて
AIが動きやすい環境を先に作れる人

画像に8つまとめたので
Claude使う人は保存しといて

[Tetsuya Mitsudomi @t_mitsudomi]

https://t.co/a6xUIqvo6V
Our review article on perioperative immunotherapy has just been published in the new English-language journal of the Japan Lung Cancer Society
I would very much welcome your comments, criticisms, and discussion.

[Tetsuya Mitsudomi @t_mitsudomi]

Immunotherapy in resectable non–small cell lung cancer; emerging clini... https://t.co/9JwSvvUfv8

[Tetsuya Mitsudomi @t_mitsudomi]

https://t.co/a6xUIqvo6V
Our review article on perioperative immunotherapy has just been published in the new English-language journal of the Japan Lung Cancer Society
I would very much welcome your comments, criticisms, and discussion.

[NatureRevClinOncol @NatRevClinOncol]

New online! Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization https://t.co/4zO7BuylVi

[LARVOL @Larvol]

Ahead of the European Lung Cancer Congress (ELCC) 2026, we asked leading AI models to forecast outcomes for high-impact lung cancer trials, before any numerical results are released.

We compared predictions across models to generate an AI consensus on expected efficacy signals across NSCLC and ES-SCLC, covering key endpoints including PFS, OS, and EFS.

Each forecast includes: hazard ratios, statistical significance (p < 0.05: Yes/No), median survival estimates, and a predicted Kaplan–Meier curve showing how outcomes may separate over time.

Highlights:
NSCLC

HARMONi: Ivonescimab + chemotherapy projected strong PFS benefit
▶️ AI consensus PFS HR: 0.36

KEYNOTE-671: Perioperative pembrolizumab expected to sustain benefit at long-term follow-up
▶️ EFS HR: 0.59 | OS HR: 0.73

TOP: Osimertinib + chemotherapy predicted to improve outcomes vs osimertinib alone
▶️ PFS HR: 0.65

OptiTROP-Lung03: Sac-TMT projected to show meaningful OS benefit
▶️ OS HR: 0.59

ES-SCLC
IMpower133: Long-term follow-up expected to maintain immunotherapy benefit
▶️ OS HR: 0.79 | PFS HR: 0.80

CAPSTONE-1: Adebrelimab + chemotherapy forecast to sustain survival advantage
▶️ OS HR: 0.76

Mixed signals

EMPOWER-Lung 1: Cemiplimab monotherapy predicted to maintain durable survival gains
▶️ OS HR: 0.61

LATIFY: Limited benefit expected for ceralasertib + durvalumab
▶️ OS HR: 0.98 (not significant)

Across trials, the AI consensus points to continued durability of immunotherapy benefits, incremental gains from combination strategies, and variable outcomes in targeted therapy settings.

Which ELCC 2026 results do you expect will beat or fall short of these forecasts?

Explore more insights and conference data from #ELCC26 👉 https://t.co/PuWKbMIQiA

#LARVOL #ELCC2026 #LungCancer #LCSM #NSCLC #SCLC #ESSCLC #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials | @Tony_Calles | @FordePatrick | @HHorinouchi | @BalazsHalmosMD | @DrSanjayPopat

[Eli Van Allen @VanAllenLab]

Here's our latest, where we explored how to augment LLMs with constantly evolving precision oncology knowledge (h/t @moalmanac), followed by collaboration with medical oncologists to test their queries - congrats Helena Jun, et al!

[Katsuaki Maehara 🇯🇵 @KatsuakiMaehara]

🫁 Early stage #NSCLC 🫁

🫁 #Perioperative treatment - Immunotherapy 🫁

🫁 Updated key clinical data including #WCLC25 &amp; #ESMO25 🫁

#lungcancer
#Immunotherapy
#LCSM

[Ohad Hammer @ohadhammer]

Similar story in SCLC with ADCs targeting B7H3, DLL3, SEZ6 all reporting strong efficacy. 15+ programs in the clinic, most will finish the race empty handed
(Table from Jefferies' note on $ZLAB)

[Tetsuya Mitsudomi @t_mitsudomi]

11/21-23にヒルトン東京でIASLC hot topic meeting -Unraveling precancer and early stage lung cancerを開催します。添付のようにdiscount codeをつかっていただくと会費が半額になりますのでふるってご参加くださいますようお願い申し上げます。

[Stephen Chun @StephenChunMD]

Amazing @IASLC #ACLC25 faculty dinner in Vietnam with @t_mitsudomi &amp; @susu_mail0513.

[Science At BMS @ScienceAtBMS]

Tomorrow at #WCLC, Dr @t_mitsudomi will present survival and health-related quality of life results with neoadjuvant chemoIO by surgical outcomes in CheckMate 816.

Join the session at 12pm CEST in Room 06. #LCSM #lungcancer

[Patrick Forde @FordePatrick]

Surgical outcomes correlation with 5 year survival with neoadj chemo IO for lung cancer in CheckMate 816 presented by the legendary Prof. @t_mitsudomi #WCLC25 overall v good outcomes, remarkably so for pts with pneumonectomy #LCSM

[Kai @bmassutis]

76.9% surgery conversion rate and 55% pathological complete response in “considered unresectable” St III after induction Tislelizumab plus Platinum-based chemotherapy: small number of patients but impressive results @OncoAlert #WCLC25

[Hidehito HORINOUCHI @HHorinouchi]

☑️#WCLC25 #LCSM Oral🆙
🔥OS by Surgical Outcomes in the CheckMate 816
🎯OS was improved regardless of surgical approach and extent of resection, and in patients with R0 resection
🎙️ @t_mitsudomi
@OncoAlert @Larvol @IASLC
https://t.co/upYlkSnChl

[Hidehito HORINOUCHI @HHorinouchi]

☑️#ASCO25 🆙
☑️#LCSM Oral, LocReg/SCLC
🔥R-ALPS: TQB2450 + /- anlotinib as maint Tx in pts with stage III NSCLC without progression following CRT
🎙️ Dr Ming Chen
🎯PFS 15.15 vs. 4.17m, HR 0.49 (0.36-0.66)
@OncoAlert @ASCO @Larvol
https://t.co/wzaSGsX5zB

[Sanjay Popat @DrSanjayPopat]

NeoADAURA,
Osi/osi-chemo/chemo neoadj
2 vs 8% PD rate
MPR 26 vs 25 vs 2%: benefit across genotype &amp; stage. Greater depth response by osi-chemo&gt;osi
Nodal downstaging in both osi arms
Osi/osi-chemo reduces PD, gets MPR

Impressive EFS by MPR vs not

#ASCO25

[Oscar Tahuahua @drtahuahua]

Adjuvant osimertinib (EGFR) and alectinib (ALK) are new standards in resectable NSCLC.

Trials like NeoADAURA, ALNEO/NAUTIKA1 evaluate perioperative (neoadj/adj) TKIs in EGFR, ALK, KRAS G12C, BRAF, RET (LIBRETO 432), NTRK &amp; MET

https://t.co/uyQMENbACl